Explore

Rapid Read Rapid Read
CXMT's Stock Market Debut Surges Over 500%, Becomes China's Most Valuable Listed Company

CXMT's Stock Market Debut Surges Over 500%, Becomes China's Most Valuable Listed Company

ChangXin Memory Technologies (CXMT), a leading Chinese manufacturer of dynamic random-access memory (DRAM) chips, has made a remarkable debut on the stock market with a 500% increase in its stock value. The company raised 57.92 billion yuan ($8.6 billion) through Asia's largest initial public offering this year. The stock opened at 49.50 yuan, significantly higher than its IPO price of 8.66 yuan, boosting the company's market capitalization to approximately 3.65 trillion yuan ($539.21 billion). This valuation surpasses that of the Industrial and Commercial Bank of China, making CXMT the most valuable listed company in China. The surge in stock value reflects strong investor enthusiasm for a domestic semiconductor leader, central to China's strategy for technological self-sufficiency. CXMT's growth is driven by the global demand for AI-related applications, which has increased the need for memory chips.
Rapid Read Rapid Read
FDA Announces Educational Webinar on Expedited IND Pilot Program

FDA Announces Educational Webinar on Expedited IND Pilot Program

The U.S. Food and Drug Administration (FDA) has announced an educational webinar scheduled for August 6, 2026, to discuss the proposed Expedited Investigational New Drug (IND) pilot program. This initiative aims to accelerate the transition from drug identification to first-in-human clinical trials. The program will establish a network of Qualified Research Institutions (QRIs), including academic medical centers, healthcare networks, and contract research organizations, to partner with sponsors in developing and reviewing protocols for IND submissions. The webinar will provide stakeholders with detailed information about the program's objectives and solicit feedback.
TheStreet TheStreet
Goldman Sachs sees writing on the wall for Eli Lilly stock

Goldman Sachs sees writing on the wall for Eli Lilly stock

Eli Lilly (LLY) stock has turned into one of the best comeback trades of 2026. Shares closed at $1,196.03 on July 24, up nearly 11% year to date after a rough start dragged the stock below $900 in the spring. Lilly shares have climbed about 39% since the company's first-quarter report, according to ...
Rapid Read Rapid Read
FDA Advisers Vote on Peptides for Drug Compounding List, Await Final Decision

FDA Advisers Vote on Peptides for Drug Compounding List, Await Final Decision

FDA advisers have narrowly voted to add six peptides to a drug compounding list, a decision that is non-binding and requires final approval from the FDA. This vote is part of ongoing efforts to regulate and expand the list of substances that can be legally compounded by pharmacies. The decision comes amid growing interest in the use of peptides for various therapeutic purposes, including their potential benefits in treating chronic conditions. The FDA's final decision will determine whether these peptides can be compounded, impacting pharmacies and patients seeking alternative treatment options.
Reuters Reuters
Hedge fund bets on rising US healthcare stocks near 5-year high, Goldman says

Hedge fund bets on rising US healthcare stocks near 5-year high, Goldman says

By Nell Mackenzie LONDON, July 27 (Reuters) - Hedge fund bets that healthcare stocks will rise neared a five-year high last week, a Goldman Sachs note showed, as cash-rich speculators believe AI-driven breakthroughs and rich financing conditions will prove profitable.
Reuters Reuters
Michigan reports 9,253 cyclosporiasis cases as infection outbreak expands

Michigan reports 9,253 cyclosporiasis cases as infection outbreak expands

By Siddhi Mahatole July 27 (Reuters) - Michigan health officials reported 9,253 cases of cyclosporiasis on Monday, an increase of 1,077 cases since their last update on Friday, as the intestinal infection outbreak grows.
Reuters Reuters
Chipmaker CXMT vaults to top of China's valuation with 466% surge in Shanghai debut

Chipmaker CXMT vaults to top of China's valuation with 466% surge in Shanghai debut

By Yantoultra Ngui and Samuel Shen SINGAPORE/SHANGHAI, July 27 (Reuters) - Shares of CXMT Corp soared 466% on their Shanghai trading debut on Monday following Asia's biggest IPO this year, catapulting the chipmaker to the top of China's stock market by valuation despite a recent selloff in global
Trendline Trendline
Novartis Reports Q2 Sales Growth and Pipeline Advancements

Novartis Reports Q2 Sales Growth and Pipeline Advancements

Novartis Reports Q2 Sales Growth and Pipeline Advancements
Trendline Trendline
Israeli Business Group Urges Local IPOs for Defense Giants Amid Global Demand

Israeli Business Group Urges Local IPOs for Defense Giants Amid Global Demand

Israeli Business Group Urges Local IPOs for Defense Giants Amid Global Demand
Trendline Trendline
Israeli Business Group Advocates for Local IPOs of Defense Giants

Israeli Business Group Advocates for Local IPOs of Defense Giants

Israeli Business Group Advocates for Local IPOs of Defense Giants
Rapid Read Rapid Read
FDA Approves Tylenol with Naproxen, Offering New Non-Opioid Pain Relief Option

FDA Approves Tylenol with Naproxen, Offering New Non-Opioid Pain Relief Option

The U.S. Food and Drug Administration (FDA) has approved Tylenol with Naproxen, marking the first over-the-counter (OTC) fixed-dose combination of acetaminophen and naproxen sodium. This new product aims to address the dissatisfaction reported by 75% of persistent pain sufferers with current pain relief options, as highlighted by a Kenvue Pain Consumer Survey. Tylenol with Naproxen combines 650 mg of acetaminophen with 220 mg of naproxen sodium, providing fast-acting and long-lasting pain relief without the need for a prescription. The product is backed by eight clinical studies demonstrating its superior efficacy compared to acetaminophen or naproxen sodium alone. The FDA has granted a three-year exclusivity period for this formulation, emphasizing its significance in non-opioid pain management.
Rapid Read Rapid Read
FDA Advisers Vote to Add Peptides to Drug Compounding List Amid Controversy

FDA Advisers Vote to Add Peptides to Drug Compounding List Amid Controversy

The FDA's Pharmacy Compounding Advisory Committee has voted to add six peptides to a drug compounding list, allowing specialty pharmacies to use them in custom medications. The decision, which is non-binding, will require FDA approval. The peptides, including BPC-157 and TB-500, have gained popularity online despite limited clinical data. The vote has sparked debate between FDA scientists, who oppose the addition due to safety concerns, and committee members who argue it could reduce harm by steering consumers away from unregulated markets.